Condition: Alzheimer s Disease · MCI Conversion to Dementia · pTau217 · Sponsor: Neurogen Biomarking LLC
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
This description comes directly from the study's public registry record.
Ansam Eghzawi, MD · +18109410076 · ansam@neurogenbiomarking.com
Elisabeth Thijssen, PhD · +16282788161 · elisabeth@neurogenbiomarking.com
Always discuss trial participation with your own doctor first.
| Insigth Hospital and Medical Center Chicago | Chicago, Illinois, United States | Recruiting |
| Insight Hospital and Medical Center Dearborn | Dearborn, Michigan, United States | Active Not Recruiting |
| Insight Institute of Neurology and Neurosurgery | Flint, Michigan, United States | Active Not Recruiting |
| Memorial Healthcare Hospital | Owosso, Michigan, United States | Active Not Recruiting |
| Wake Forest Baptist Medical Center | Winston-Salem, North Carolina, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07701161